<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:01:51Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7767634" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7767634</identifier>
        <datestamp>2020-12-31</datestamp>
        <setSpec>ehj</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Eur Heart J</journal-id>
              <journal-id journal-id-type="iso-abbrev">Eur Heart J</journal-id>
              <journal-id journal-id-type="publisher-id">eurheartj</journal-id>
              <journal-title-group>
                <journal-title>European Heart Journal</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0195-668X</issn>
              <issn pub-type="epub">1522-9645</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7767634</article-id>
              <article-id pub-id-type="pmcid">PMC7767634</article-id>
              <article-id pub-id-type="pmc-uid">7767634</article-id>
              <article-id pub-id-type="pmid">32860414</article-id>
              <article-id pub-id-type="pmid">32860414</article-id>
              <article-id pub-id-type="doi">10.1093/eurheartj/ehaa658</article-id>
              <article-id pub-id-type="publisher-id">ehaa658</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Fast Track Congress</subject>
                  <subj-group subj-group-type="category-toc-heading">
                    <subject>Arrhythmias</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="category-oup-series">
                  <subject>Editor's Choice</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00200</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>Eurheartj/1</subject>
                  <subject>Eurheartj/2</subject>
                  <subject>Eurheartj/3</subject>
                  <subject>Eurheartj/40</subject>
                  <subject>Eurheartj/39</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8129-8520</contrib-id>
                  <name>
                    <surname>Haldar</surname>
                    <given-names>Shouvik</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                  <aff><institution>National Heart and Lung Institute, Imperial College London</institution>, Cale Street, London SW3 6LY, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4828-5768</contrib-id>
                  <name>
                    <surname>Khan</surname>
                    <given-names>Habib Rehman</given-names>
                  </name>
                  <aff><institution>National Heart and Lung Institute, Imperial College London</institution>, Cale Street, London SW3 6LY, <country country="GB">UK</country></aff>
                  <aff><institution>London Health Sciences Centre, University of Western Ontario</institution>, 800 Commissioners Rd E, London ON N6A 5W9, <country country="CA">Canada</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Boyalla</surname>
                    <given-names>Vennela</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                  <aff><institution>National Heart and Lung Institute, Imperial College London</institution>, Cale Street, London SW3 6LY, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7401-6281</contrib-id>
                  <name>
                    <surname>Kralj-Hans</surname>
                    <given-names>Ines</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jones</surname>
                    <given-names>Simon</given-names>
                  </name>
                  <aff><institution>New York University</institution>, Langone Health, 227 East 30th Street, New York, NY 10016, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1086-1624</contrib-id>
                  <name>
                    <surname>Lord</surname>
                    <given-names>Joanne</given-names>
                  </name>
                  <aff><institution>Southampton Health Technology Assessment Centre, University of Southampton</institution>, University Road, Southampton SO17 1BJ, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Onyimadu</surname>
                    <given-names>Oluchukwu</given-names>
                  </name>
                  <aff><institution>Southampton Health Technology Assessment Centre, University of Southampton</institution>, University Road, Southampton SO17 1BJ, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Satishkumar</surname>
                    <given-names>Anitha</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bahrami</surname>
                    <given-names>Toufan</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>De Souza</surname>
                    <given-names>Anthony</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Clague</surname>
                    <given-names>Jonathan R</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3410-0814</contrib-id>
                  <name>
                    <surname>Francis</surname>
                    <given-names>Darrel P</given-names>
                  </name>
                  <aff><institution>National Heart and Lung Institute, Imperial College London</institution>, Cale Street, London SW3 6LY, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4104-1821</contrib-id>
                  <name>
                    <surname>Hussain</surname>
                    <given-names>Wajid</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8274-5676</contrib-id>
                  <name>
                    <surname>Jarman</surname>
                    <given-names>Julian W</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jones</surname>
                    <given-names>David Gareth</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                  <aff><institution>National Heart and Lung Institute, Imperial College London</institution>, Cale Street, London SW3 6LY, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Zhong</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mediratta</surname>
                    <given-names>Neeraj</given-names>
                  </name>
                  <aff><institution>Liverpool Heart and Chest Hospital</institution>, Thomas Dr, Liverpool L14 3PE, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hyde</surname>
                    <given-names>Jonathan</given-names>
                  </name>
                  <aff><institution>Brighton and Sussex University Hospitals NHS Trust</institution>, Royal Alexandra Children’s Hospital, Eastern Road, Brighton BN2 5BE, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lewis</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <aff><institution>Brighton and Sussex University Hospitals NHS Trust</institution>, Royal Alexandra Children’s Hospital, Eastern Road, Brighton BN2 5BE, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1768-7457</contrib-id>
                  <name>
                    <surname>Mohiaddin</surname>
                    <given-names>Raad</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                  <aff><institution>National Heart and Lung Institute, Imperial College London</institution>, Cale Street, London SW3 6LY, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3505-9905</contrib-id>
                  <name>
                    <surname>Salukhe</surname>
                    <given-names>Tushar V</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                  <aff><institution>National Heart and Lung Institute, Imperial College London</institution>, Cale Street, London SW3 6LY, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Murphy</surname>
                    <given-names>Caroline</given-names>
                  </name>
                  <aff><institution>Clinical Trials Unit, Kings College London</institution>, Institute of Psychiatry, 16 De Crespigny Park, London SE5 8A, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kelly</surname>
                    <given-names>Joanna</given-names>
                  </name>
                  <aff><institution>Clinical Trials Unit, Kings College London</institution>, Institute of Psychiatry, 16 De Crespigny Park, London SE5 8A, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5992-2315</contrib-id>
                  <name>
                    <surname>Khattar</surname>
                    <given-names>Rajdeep S</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5631-4496</contrib-id>
                  <name>
                    <surname>Toff</surname>
                    <given-names>William D</given-names>
                  </name>
                  <aff><institution>Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Glenfield Hospital</institution>, Groby Road, Leicester LE3 9QP, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9385-1298</contrib-id>
                  <name>
                    <surname>Markides</surname>
                    <given-names>Vias</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                  <aff><institution>National Heart and Lung Institute, Imperial College London</institution>, Cale Street, London SW3 6LY, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McCready</surname>
                    <given-names>James</given-names>
                  </name>
                  <aff><institution>Brighton and Sussex University Hospitals NHS Trust</institution>, Royal Alexandra Children’s Hospital, Eastern Road, Brighton BN2 5BE, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3490-090X</contrib-id>
                  <name>
                    <surname>Gupta</surname>
                    <given-names>Dhiraj</given-names>
                  </name>
                  <aff><institution>Liverpool Heart and Chest Hospital</institution>, Thomas Dr, Liverpool L14 3PE, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6484-4961</contrib-id>
                  <name>
                    <surname>Wong</surname>
                    <given-names>Tom</given-names>
                  </name>
                  <aff><institution>Royal Brompton &amp; Harefield NHS Foundation Trust</institution>, Sydney Street, London SW3 6NP, <country country="GB">UK</country></aff>
                  <aff><institution>National Heart and Lung Institute, Imperial College London</institution>, Cale Street, London SW3 6LY, <country country="GB">UK</country></aff>
                  <xref rid="ehaa658-cor1" ref-type="corresp"/>
                  <!--tom.wong@imperial.ac.uk-->
                </contrib>
                <on-behalf-of>on behalf of the CASA-AF Investigators</on-behalf-of>
              </contrib-group>
              <author-notes>
                <corresp id="ehaa658-cor1">Corresponding author. Tel: +44 20 7351 8619, Fax: +44 20 7351 8629, Email: <email>tom.wong@imperial.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <day>14</day>
                <month>12</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2020-08-29">
                <day>29</day>
                <month>8</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>29</day>
                <month>8</month>
                <year>2020</year>
              </pub-date>
              <volume>41</volume>
              <issue>47</issue>
              <issue-title>Focus Issue on Arrhythmias</issue-title>
              <fpage>4471</fpage>
              <lpage>4480</lpage>
              <history>
                <date date-type="received">
                  <day>30</day>
                  <month>6</month>
                  <year>2020</year>
                </date>
                <date date-type="rev-recd">
                  <day>15</day>
                  <month>7</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>30</day>
                  <month>7</month>
                  <year>2020</year>
                </date>
                <date date-type="editorial-decision">
                  <day>27</day>
                  <month>7</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.</copyright-statement>
                <copyright-year>2020</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="ehaa658.pdf"/>
              <related-article related-article-type="companion" ext-link-type="doi" id="RA2" xlink:href="10.1093/eurheartj/ehaa751"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s1">
                  <title>Aims </title>
                  <p>Long-standing persistent atrial fibrillation (LSPAF) is challenging to treat with suboptimal catheter ablation (CA) outcomes. Thoracoscopic surgical ablation (SA) has shown promising efficacy in atrial fibrillation (AF). This multicentre randomized controlled trial tested whether SA was superior to CA as the first interventional strategy in <italic toggle="yes">de novo</italic> LSPAF.</p>
                </sec>
                <sec id="s2">
                  <title>Methods and results </title>
                  <p>We randomized 120 LSPAF patients to SA or CA. All patients underwent predetermined lesion sets and implantable loop recorder insertion. Primary outcome was single procedure freedom from AF/atrial tachycardia (AT) ≥30 s without anti-arrhythmic drugs at 12 months. Secondary outcomes included clinical success (≥75% reduction in AF/AT burden); procedure-related serious adverse events; changes in patients’ symptoms and quality-of-life scores; and cost-effectiveness. At 12 months, freedom from AF/AT was recorded in 26% (14/54) of patients in SA vs. 28% (17/60) in the CA group [OR 1.128, 95% CI (0.46–2.83), <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.83]. Reduction in AF/AT burden ≥75% was recorded in 67% (36/54) vs. 77% (46/60) [OR 1.13, 95% CI (0.67–4.08), <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.3] in SA and CA groups, respectively. Procedure-related serious adverse events within 30 days of intervention were reported in 15% (8/55) of patients in SA vs. 10% (6/60) in CA, <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.46. One death was reported after SA. Improvements in AF symptoms were greater following CA. Over 12 months, SA was more expensive and provided fewer quality-adjusted life-years (QALYs) compared with CA (0.78 vs. 0.85, <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.02).</p>
                </sec>
                <sec id="s3">
                  <title>Conclusion </title>
                  <p>Single procedure thoracoscopic SA is not superior to CA in treating LSPAF. Catheter ablation provided greater improvements in symptoms and accrued significantly more QALYs during follow-up than SA.</p>
                </sec>
                <sec id="s4">
                  <title>Clinical Trial Registration</title>
                  <p>ISRCTN18250790 and ClinicalTrials.gov: NCT02755688</p>
                  <p>
                    <fig position="float" id="ehaa658-F4a">
                      <graphic xlink:href="ehaa658f4" position="float"/>
                    </fig>
                  </p>
                </sec>
              </abstract>
              <abstract abstract-type="graphical">
                <title>Graphical Abstract</title>
                <p>
                  <fig position="float" id="ehaa658-F5">
                    <graphic xlink:href="ehaa658f4" position="float"/>
                  </fig>
                </p>
              </abstract>
              <kwd-group>
                <kwd>Arrhythmia</kwd>
                <kwd>Electrophysiology</kwd>
                <kwd>Atrial fibrillation</kwd>
                <kwd>Catheter ablation</kwd>
                <kwd>Epicardial PVI</kwd>
                <kwd>Implantable loop recorder</kwd>
              </kwd-group>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Efficacy and Mechanism Evaluation</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Programme, a Medical Research Council</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institute for Health Research</institution>
                      <institution-id institution-id-type="DOI">10.13039/501100000272</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>NIHR</institution>
                      <institution-id institution-id-type="DOI">10.13039/100006662</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>12/127/127</award-id>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>MRC</institution>
                      <institution-id institution-id-type="DOI">10.13039/501100000265</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Department of Health and Social Care</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="10"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p>
              <bold>See page 4481 for the editorial comment on this article (doi: <related-article related-article-type="companion" ext-link-type="doi" id="RA1" xlink:href="10.1093/eurheartj/ehaa751">10.1093/eurheartj/ehaa751</related-article>)</bold>
            </p>
            <sec>
              <title>Introduction</title>
              <p>Worldwide, atrial fibrillation (AF) affects 1–2% of the population and its prevalence is increasing.<xref rid="ehaa658-B1" ref-type="bibr"><sup>1</sup></xref> Atrial fibrillation is associated with lower quality of life, increased morbidity and mortality, and a large number of hospital admissions.<xref rid="ehaa658-B2" ref-type="bibr"><sup>2</sup></xref>
 <sup>,</sup>
 <xref rid="ehaa658-B3" ref-type="bibr"><sup>3</sup></xref> Management of AF requires considerable health resources estimated at 2% of the NHS budget in the UK.<xref rid="ehaa658-B3" ref-type="bibr"><sup>3</sup></xref>
 <sup>,</sup>
 <xref rid="ehaa658-B4" ref-type="bibr"><sup>4</sup></xref></p>
              <p>Atrial fibrillation management consists of stroke prevention with anticoagulants and ventricular rate control with pharmacological agents. For rhythm control, catheter ablation (CA) is superior to anti-arrhythmic drugs (AAD) and is routinely offered to patients with symptomatic AF.<xref rid="ehaa658-B3" ref-type="bibr"><sup>3</sup></xref>
 <sup>,</sup>
 <xref rid="ehaa658-B5" ref-type="bibr"><sup>5</sup></xref>
 <sup>,</sup>
 <xref rid="ehaa658-B6" ref-type="bibr"><sup>6</sup></xref> Catheter ablation can reliably maintain sinus rhythm (SR) in 60–80% of patients with paroxysmal AF<xref rid="ehaa658-B3" ref-type="bibr"><sup>3</sup></xref> and is almost as effective (≈60%) in early persistent AF.<xref rid="ehaa658-B7" ref-type="bibr"><sup>7</sup></xref> However, long-standing persistent AF (LSPAF), defined as continuous AF greater than 12 months, represents the most advanced end of the disease spectrum and CA outcomes in this setting are suboptimal, often requiring multiple CA procedures to establish normal heart rhythm.<xref rid="ehaa658-B8" ref-type="bibr"><sup>8</sup></xref>
 <sup>,</sup>
 <xref rid="ehaa658-B9" ref-type="bibr"><sup>9</sup></xref></p>
              <p>Thoracoscopic surgical ablation (SA) was proposed to be more effective due to the direct application of transmural and contiguous lesions as well as the ability to ablate ganglionic plexi (GP) and exclude the left atrial appendage (LAA). Previous non-randomized studies in LSPAF utilizing intermittent cardiac rhythm monitoring reported encouraging results.<xref rid="ehaa658-B10" ref-type="bibr"><sup>10</sup></xref>
 <sup>,</sup>
 <xref rid="ehaa658-B11" ref-type="bibr"><sup>11</sup></xref> Continuous cardiac rhythm monitoring is essential to accurately assess AF recurrences as well as estimate AF burden reduction, an important marker of clinical success.<xref rid="ehaa658-B12" ref-type="bibr"><sup>12–14</sup></xref></p>
              <p>In this randomized controlled trial (RCT), we sought to determine whether thoracoscopic SA was superior to CA as a first-line procedure in <italic toggle="yes">de novo</italic> LSPAF patients, refractory or intolerant to at least one AAD (Class 1 or 3). We compared the effectiveness, safety, impact on quality of life, and cost-effectiveness of these two treatments.</p>
            </sec>
            <sec sec-type="methods">
              <title>Methods</title>
              <sec>
                <title>Trial design</title>
                <p>CASA-AF is a prospective, multicentre, RCT conducted at 4 high-volume UK centres. The trial was approved by the UK NRES ethical review board (15/SC/0023) and conforms to the Declaration of Helsinki. The published protocol was in accordance with the Interventional Trials (SPIRIT) 2013 statement.<xref rid="ehaa658-B15" ref-type="bibr"><sup>15</sup></xref>
 <sup>,</sup>
 <xref rid="ehaa658-B16" ref-type="bibr"><sup>16</sup></xref> The conduct of the study was overseen by two independent bodies, the Data Monitoring and the Trial Steering Committees.</p>
              </sec>
              <sec>
                <title>Study participants</title>
                <p>Adults with symptomatic LSPAF, EHRA symptom score &gt;2, left ventricular ejection fraction ≥40%, referred for treatment and suitable for both procedures were eligible. Exclusion criteria included valvular heart disease (severity greater than mild) and previous cardiothoracic surgery (including surgical AF interventions). Detailed inclusion and exclusion criteria are provided in the <xref rid="sup1" ref-type="supplementary-material">Supplementary material (<italic toggle="yes">Table</italic> A1</xref>). All participants provided written informed consent.</p>
                <sec>
                  <title>Treatment allocation</title>
                  <p>Patients were randomly assigned to treatment groups by computer-generated sequence in a 1:1 ratio using minimization. The system used the study site, participant’s sex, and the diameter of the left atrium (&lt;50 and ≥50 mm) as stratifying variables. Treatment allocation was concealed and heart rhythm assessors, the trial statistician and the health economist were blinded to treatment arms. Double blinding in this study was not possible due to the marked differences in the procedural techniques.</p>
                </sec>
              </sec>
              <sec>
                <title>Study procedures</title>
                <sec>
                  <title>Procedures</title>
                  <p>Procedure details and pre- and post-ablation patient management have been previously published in the trial protocol.<xref rid="ehaa658-B16" ref-type="bibr"><sup>16</sup></xref> In SA, radiofrequency ablation was performed under direct vision starting with pulmonary vein isolation (PVI), then GP ablation, followed by linear roof and inferior line ablation to create a posterior wall box lesion. The LAA was then excluded using the AtriClip<sup>®</sup> LAA excluder system (AtriCure). (<italic toggle="yes"><xref rid="ehaa658-F4" ref-type="fig">Take home figure</xref></italic>, Left panel).</p>
                  <fig position="float" id="ehaa658-F4">
                    <label>Take home figure</label>
                    <caption>
                      <p><italic toggle="yes">Left:</italic> Schematic representation of lesion placement in catheter and surgical ablation. Most lesions were performed by radiofrequency ablation (thin red or blue lines) but left atrial appendage (LAA) was occluded with a clip (thick red line) and the Ligament of Marshall (LoM) was dissected (dashed green line). <italic toggle="yes">Middle:</italic> Kaplan–Meier survival plots illustrating freedom from AF/AT (left) and clinical success (right) of both treatments. <italic toggle="yes">Right:</italic> Graphical representation of symptoms improvement (EHRA score reduction), QALY gained and the total costs associated with both treatments at 12 months.</p>
                    </caption>
                    <graphic xlink:href="ehaa658f4" position="float"/>
                  </fig>
                  <p>We mandated the presence of a cardiac electrophysiologist to ensure conduction block testing for all lesions.<xref rid="ehaa658-B17" ref-type="bibr"><sup>17</sup></xref> Cardiac surgeons had to be experienced in video-assisted thoracoscopic AF surgery with a minimum of 20 procedures performed as the primary operator.</p>
                  <p>In CA, trans-septal puncture was followed by point-by-point radiofrequency ablation including PVI, roof and inferior line to create a posterior wall box lesion. A lateral mitral isthmus and cavotricuspid isthmus line completed the lesion set (<italic toggle="yes"><xref rid="ehaa658-F4" ref-type="fig">Take home figure</xref></italic>, Left panel).</p>
                  <p>Conduction testing to confirm bi-directional block for all lesions was done in the usual manner in both treatment arms with additional ablation where necessary. In both groups, an implantable loop recorder (ILR) was implanted at the end of the procedure.</p>
                </sec>
                <sec>
                  <title>Follow-up schedule</title>
                  <p>Study assessments and frequency of follow-up visits are detailed in <italic toggle="yes">Figure <xref rid="ehaa658-F1" ref-type="fig">1</xref></italic>. AAD therapy (flecainide, procainamide, amiodarone, or sotalol) was terminated before the end of the blanking period (3 months). Recurrence of symptomatic AF during the blanking period was treated with DC cardioversion with or without AADs. Patients were offered percutaneous CA if AF/atrial tachycardia (AT) recurred outside the blanking period.
</p>
                  <fig position="float" id="ehaa658-F1">
                    <label>Figure 1</label>
                    <caption>
                      <p>Schematic representation of CASA-AF study design. AAD, anti-arrhythmic drugs; AF, atrial fibrillation; AFEQT, AF Effect on QualiTy-of-life questionnaire; AT, atrial tachycardia; CMRI, cardiac magnetic resonance imaging; ECG, electrocardiogram; EHRA, European Heart Rhythm Association score for AF; EQ-5D-5L, quality of life questionnaire; HEQ, health economic questionnaire; IL, implantable loop recorder; TTE, trans thoracic echocardiogram.</p>
                    </caption>
                    <graphic xlink:href="ehaa658f1" position="float"/>
                  </fig>
                </sec>
                <sec>
                  <title>Implantable loop recorder</title>
                  <p>Continuous cardiac monitoring was provided by a Reveal LINQ ILR (Medtronic, Minneapolis, MN) with two aggressive AF/AT detection algorithms.<xref rid="ehaa658-B18" ref-type="bibr"><sup>18</sup></xref> A blinded senior cardiac physiologist regularly analysed data to produce monthly heart rhythm assessments. Further details of the ILR analysis, programming and data quality control can be found in the <xref rid="sup1" ref-type="supplementary-material">Supplementary material Sections 5–7</xref>.</p>
                </sec>
              </sec>
              <sec>
                <title>Study endpoints</title>
                <p>The primary outcome was freedom from AF/AT ≥30 s after a single ablation procedure, without AADs during the 12 months follow-up, excluding blanking period.</p>
                <p>Secondary outcomes included a safety endpoint (intervention-related serious adverse event, defined as permanent injury or death, one that requires unplanned intervention for treatment, or one that prolongs or requires unplanned hospitalization for &gt;48 h), clinical success rate (reduction of AF/AT burden ≥75%), changes in symptoms [European Heart Rhythm Association (EHRA) overall score] and quality-of-life scores [Atrial Fibrillation Effect on QualiTy-of-life Questionnaire (AFEQT); EQ-5D-5L UK cross-walk index score],<xref rid="ehaa658-B19" ref-type="bibr"><sup>19</sup></xref> and within-trial health economic assessment using quality-adjusted life-years (QALYs) and healthcare costs (UK £2019) accrued over the 12 months of follow-up.</p>
                <p>Independent reviews of heart rhythm and safety endpoints were conducted by committees blinded to treatment allocation.</p>
              </sec>
              <sec>
                <title>Statistical analysis</title>
                <p>The sample size calculations were based on the effect size estimates available in the literature and from our own pilot study (see <xref rid="sup1" ref-type="supplementary-material">Supplementary material Section 3</xref>). Intention to treat analyses were performed on complete cases. Sensitivity analyses were used to explore the impact of missing data, non-compliance, and withdrawals. R statistical software version 4.0.0 was used to analyse data. Sample size (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>120, 10% attrition rate included) was calculated to allow 90% power and 5% significance level to detect a clinically important difference in the primary outcome. The primary outcome of the trial was the proportion of treated participants, free from AF/AT episodes lasting ≥30 s within 12 months after a single procedure and without AADs. Arrhythmia-free patients were identified through monthly ILR data assessments from the end of the blanking period to the end of the 12 months follow-up (<xref rid="sup1" ref-type="supplementary-material">Supplementary material Section 4</xref>). Burden of AF/AT reduced ≥75% of the time every month was a marker of clinical success of the procedure. Chi-squared test and logistic regression were used for comparison between the trial arms. Freedom from AF/AT and burden reduction were also analysed using Kaplan–Meier survival curves.</p>
                <p>Continuous data were analysed by either Student’s <italic toggle="yes">t</italic>-test or Mann–Whitney test and presented as mean (±standard deviation-SD), mean (95% confidence interval) or median (interquartile range-IQR) depending upon distribution of obtained data. A <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.05 is considered significant.</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <sec>
                <title>Patients</title>
                <p>Patient recruitment took place between September 2015 and June 2018. Of 120 patients randomized (SA = 60, CA = 60), five patients withdrew consent post-randomisation in the SA arm and were excluded from analyses (modified intent to treat principle). Study treatment was received by 115 patients of whom 110 completed all follow-up. Patient flow is shown in <italic toggle="yes">Figure <xref rid="ehaa658-F2" ref-type="fig">2</xref></italic>.
</p>
                <fig position="float" id="ehaa658-F2">
                  <label>Figure 2</label>
                  <caption>
                    <p>CONSORT diagram.</p>
                  </caption>
                  <graphic xlink:href="ehaa658f2" position="float"/>
                </fig>
                <p>Patients had a mean age of 62.3 (±9.6) years, were predominantly male (74%), with mean left atrial diameter 44.7 (±6) mm and in continuous AF for a median (IQR) of 22 (16–31) months.</p>
                <p>Baseline characteristics are shown in <italic toggle="yes">Table <xref rid="ehaa658-T1" ref-type="table">1</xref></italic>.
</p>
                <table-wrap position="float" id="ehaa658-T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline characteristics of CASA-AF study participants</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1">Characteristics</th>
                        <th rowspan="1" colspan="1">All (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>120)</th>
                        <th rowspan="1" colspan="1">CA (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>60)</th>
                        <th rowspan="1" colspan="1">SA (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>60)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Age (years), mean (SD)</td>
                        <td rowspan="1" colspan="1">62.3 (9.6)</td>
                        <td rowspan="1" colspan="1">60.8 (10.1)</td>
                        <td rowspan="1" colspan="1">63.8 (8.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Male sex, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">89 (74.2)</td>
                        <td rowspan="1" colspan="1">45 (75)</td>
                        <td rowspan="1" colspan="1">44 (73.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), median (IQR)</td>
                        <td rowspan="1" colspan="1">30.2 (27–32.8)</td>
                        <td rowspan="1" colspan="1">30.6 (27.6–33.3)</td>
                        <td rowspan="1" colspan="1">29.7 (26.1–32.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Townsend deprivation index, median (IQR)</td>
                        <td rowspan="1" colspan="1">−0.4 (−2.2–1.4)</td>
                        <td rowspan="1" colspan="1">−0.7 (−2.5–0.6)</td>
                        <td rowspan="1" colspan="1">−0.1 (−2–1.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">IMD score, median (IQR)</td>
                        <td rowspan="1" colspan="1">12.7 (7.7–22.3)</td>
                        <td rowspan="1" colspan="1">11.1 (5.5–21.5)</td>
                        <td rowspan="1" colspan="1">14 (8.7–22.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ethnicity, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> White</td>
                        <td rowspan="1" colspan="1">112 (93)</td>
                        <td rowspan="1" colspan="1">57 (95)</td>
                        <td rowspan="1" colspan="1">55 (92)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Asian</td>
                        <td rowspan="1" colspan="1">1 (1)</td>
                        <td rowspan="1" colspan="1">0 (0)</td>
                        <td rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Black<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">3 (3)</td>
                        <td rowspan="1" colspan="1">1 (2)</td>
                        <td rowspan="1" colspan="1">2 (3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Middle-eastern</td>
                        <td rowspan="1" colspan="1">1 (1)</td>
                        <td rowspan="1" colspan="1">1 (2)</td>
                        <td rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Systolic blood pressure (mmHg), mean (SD)</td>
                        <td rowspan="1" colspan="1">127.9 (16.7)</td>
                        <td rowspan="1" colspan="1">126.6 (16.3)</td>
                        <td rowspan="1" colspan="1">129.1 (17.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Diastolic blood pressure (mmHg), mean (SD)</td>
                        <td rowspan="1" colspan="1">79.8 (12)</td>
                        <td rowspan="1" colspan="1">81.5 (13.1)</td>
                        <td rowspan="1" colspan="1">78 (10.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ejection fraction (%), mean (SD)</td>
                        <td rowspan="1" colspan="1">56.9 (8.9)</td>
                        <td rowspan="1" colspan="1">55.2 (8.9)</td>
                        <td rowspan="1" colspan="1">58.8 (8.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Left atrial diameter (mm), mean (SD)</td>
                        <td rowspan="1" colspan="1">44.6 (5.9)</td>
                        <td rowspan="1" colspan="1">44.6 (6)</td>
                        <td rowspan="1" colspan="1">44.7 (5.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Diagnosis of persistent AF to procedure (months), median (IQR)</td>
                        <td rowspan="1" colspan="1">22 (16–31)</td>
                        <td rowspan="1" colspan="1">19.5 (15–29.2)</td>
                        <td rowspan="1" colspan="1">25 (19–35.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Medical history, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Hypertension</td>
                        <td rowspan="1" colspan="1">56 (46.7)</td>
                        <td rowspan="1" colspan="1">23 (38.3)</td>
                        <td rowspan="1" colspan="1">33 (55)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Diabetes</td>
                        <td rowspan="1" colspan="1">9 (7.5)</td>
                        <td rowspan="1" colspan="1">4 (6.7)</td>
                        <td rowspan="1" colspan="1">5 (8.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Coronary artery disease</td>
                        <td rowspan="1" colspan="1">13 (10.8)</td>
                        <td rowspan="1" colspan="1">7 (11.7)</td>
                        <td rowspan="1" colspan="1">6 (10)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Stroke, TIA or thromboembolism</td>
                        <td rowspan="1" colspan="1">5 (4.2)</td>
                        <td rowspan="1" colspan="1">1 (1.7)</td>
                        <td rowspan="1" colspan="1">4 (6.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>VASc score<italic toggle="yes">, n</italic> (%)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 0</td>
                        <td rowspan="1" colspan="1">34 (28.3)</td>
                        <td rowspan="1" colspan="1">21 (35)</td>
                        <td rowspan="1" colspan="1">13 (21.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 1</td>
                        <td rowspan="1" colspan="1">34 (28.3)</td>
                        <td rowspan="1" colspan="1">18 (30)</td>
                        <td rowspan="1" colspan="1">16 (26.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 2</td>
                        <td rowspan="1" colspan="1">27 (22.5)</td>
                        <td rowspan="1" colspan="1">11 (18.3)</td>
                        <td rowspan="1" colspan="1">16 (26.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ≥3</td>
                        <td rowspan="1" colspan="1">25 (20.8)</td>
                        <td rowspan="1" colspan="1">10 (16.7)</td>
                        <td rowspan="1" colspan="1">15 (25)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HASBLED score<italic toggle="yes">, n</italic> (%)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 0</td>
                        <td rowspan="1" colspan="1">23 (19.2)</td>
                        <td rowspan="1" colspan="1">12 (20)</td>
                        <td rowspan="1" colspan="1">11 (8.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 1</td>
                        <td rowspan="1" colspan="1">49 (40.8)</td>
                        <td rowspan="1" colspan="1">30 (50)</td>
                        <td rowspan="1" colspan="1">19 (31.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 2</td>
                        <td rowspan="1" colspan="1">39 (32.5)</td>
                        <td rowspan="1" colspan="1">15 (25)</td>
                        <td rowspan="1" colspan="1">24 (40)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ≥3</td>
                        <td rowspan="1" colspan="1">9 (7.5)</td>
                        <td rowspan="1" colspan="1">3 (5)</td>
                        <td rowspan="1" colspan="1">6 (10)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn1">
                      <p>AF, atrial fibrillation; BMI, body mass index; CA, catheter ablation; CHA<sub>2</sub>DS<sub>2</sub>VASc, congestive heart failure, high blood pressure, Age 75, Diabetes, previous Stroke or clot, Vascular disease, Age 65–74, Sex; HASBLED, hypertension; Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile INR (international normalized ratio), Elderly, Drug/alcohol usage; IMD, indices of multiple deprivation; IQR, interquartile range; SA, surgical ablation; SD, standard deviation; TIA, transient ischaemic attack.</p>
                    </fn>
                    <fn id="tblfn2">
                      <label>a</label>
                      <p>Including African-Caribbean.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>Procedures</title>
                <p>The procedural characteristics are shown in <italic toggle="yes">Table <xref rid="ehaa658-T2" ref-type="table">2</xref></italic>. Median duration of SA was significantly longer (265 min; IQR: 220–310) than CA (219 min; IQR: 192–261), <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.002. Pulmonary vein isolation (all PVs) during SA was faster than in CA, with a median ablation time of 3.8 (2.6–5.9) vs. 31 (25.5–38.6) min (<italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.001). Median length of hospital stay was longer for SA than for CA [6 (5–7) vs. 2 (2–2) days, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.001]. Further details are provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary material (<italic toggle="yes">Table A2</italic></xref>).
</p>
                <table-wrap position="float" id="ehaa658-T2">
                  <label>Table 2</label>
                  <caption>
                    <p>Comparison of procedural characteristics in patients who had catheter ablation (<italic toggle="yes">n</italic> = 60) or surgical ablation (<italic toggle="yes">n</italic> = 49)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th rowspan="1" colspan="1">CA, <italic toggle="yes">N</italic> = 60</th>
                        <th rowspan="1" colspan="1">SA, <italic toggle="yes">N</italic> = 49<xref rid="tblfn5" ref-type="table-fn"><sup>*</sup></xref></th>
                        <th rowspan="1" colspan="1">Mann–Whitney test (<italic toggle="yes">P</italic>-value)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Total procedure time (min)</td>
                        <td rowspan="1" colspan="1">219 (191.5–261.2)</td>
                        <td rowspan="1" colspan="1">265 (220–310)</td>
                        <td rowspan="1" colspan="1">0.002</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Fluoroscopy time (min)</td>
                        <td rowspan="1" colspan="1">17 (11–24)</td>
                        <td rowspan="1" colspan="1">—</td>
                        <td rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Total ablation time (min)</td>
                        <td rowspan="1" colspan="1">67 (53–79)</td>
                        <td rowspan="1" colspan="1">15 (13–22)</td>
                        <td rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Radiation dose (cGycm<sup>2</sup>)</td>
                        <td rowspan="1" colspan="1">1121 (594.5–1844.5)</td>
                        <td rowspan="1" colspan="1">—</td>
                        <td rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Length of stay (days)</td>
                        <td rowspan="1" colspan="1">2 (2–2)</td>
                        <td rowspan="1" colspan="1">6 (5–7)</td>
                        <td rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn3">
                      <p>Data are presented as median (IQR).</p>
                    </fn>
                    <fn id="tblfn4">
                      <p>CA, catheter ablation; IQR, interquartile range; SA, surgical ablation.</p>
                    </fn>
                    <fn id="tblfn5">
                      <label>*</label>
                      <p>Data from six patients who crossed over from SA to CA group are not included in this table.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>All 60 patients randomized to CA underwent ablation, compared with 55 in the SA arm, due to withdrawals post-randomization. In the SA group, six patients crossed over to CA due to lung or cardiac adhesions precluding access for SA and two patients had incomplete lesion sets due to adverse anatomical features: one patient did not have the left pulmonary vein (PV) isolated nor the LAA excluded, and the other did not have LAA exclusion.</p>
              </sec>
              <sec>
                <title>Primary and secondary endpoints</title>
                <sec>
                  <title>Primary endpoint</title>
                  <p>Freedom from AF/AT ≥30 s was recorded in 26% (14/54) of patients in SA and 28% (17/60) in the CA group following a single procedure and without AADs [OR 1.128, 95% CI (0.46–2.82), <italic toggle="yes">P</italic> = 0.84] (<italic toggle="yes"><xref rid="ehaa658-F4" ref-type="fig">Take home figure</xref></italic>, Middle panel)</p>
                  <p>One patient did not have ILR data due to non-compliance; we used their quarterly 12-lead ECGs to establish freedom from AF/AT. One patient died after SA, so they were excluded from these analyses.</p>
                  <p>Sensitivity analyses including a per-protocol and multiple imputation techniques for missing data did not change the results of the comparisons.</p>
                </sec>
                <sec>
                  <title>Secondary endpoints</title>
                  <p>Single procedure clinical success was achieved in 66% (36/54) of patients in the SA arm compared with 77% (46/60) in the CA arm [OR 1.64, 95% CI (0.67–4.84), <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.3] (<italic toggle="yes"><xref rid="ehaa658-F4" ref-type="fig">Take home figure</xref></italic>, Middle panel). Of those that did not achieve clinical success, 18% (10/54) in the SA and 15% (9/60) in the CA arm, had redo CA procedures [OR 1.29, 95% CI (0.48–3.46), <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.31].</p>
                  <p>Procedure-related serious adverse events within 30 days of the intervention (<italic toggle="yes">Table <xref rid="ehaa658-T3" ref-type="table">3</xref></italic>) occurred in 15% (8/55) of patients in the SA arm compared with 10% (6/60) in the CA arm (<italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.46). Over the 12-month follow-up period procedure-related serious adverse events (<xref rid="sup1" ref-type="supplementary-material">Supplementay material <italic toggle="yes">Table A4</italic></xref>) were recorded in 18% (10/55) of participants after SA, compared with 15% (9/60) after CA arm (<italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.65). Procedure-related adverse events rate over the 12-month follow-up period (<xref rid="sup1" ref-type="supplementary-material">Supplementary material <italic toggle="yes">Table A5</italic></xref>) was greater in the SA than the CA arm: 40% (22/55) vs. 15% (9/60) [OR 3.78, 95% CI (1.55–9.21), <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.003]. One death in the SA arm occurred 3 weeks post-procedure due to sepsis complicated by multi-organ failure and bleeding oesophageal and gastric ulcers.
</p>
                  <table-wrap position="float" id="ehaa658-T3">
                    <label>Table 3</label>
                    <caption>
                      <p>Procedure-related serious adverse events within 30 days of the ablation</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col valign="top" align="left" span="1"/>
                        <col valign="top" align="center" span="1"/>
                        <col valign="top" align="center" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="1" colspan="1">Serious adverse event</th>
                          <th rowspan="1" colspan="1">Catheter ablation (<italic toggle="yes">n</italic> = 60)</th>
                          <th rowspan="1" colspan="1">Surgical ablation (<italic toggle="yes">n</italic> = 55)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="1" colspan="1">Anaphylactic shock</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Chest infection</td>
                          <td rowspan="1" colspan="1">4 (7)</td>
                          <td rowspan="1" colspan="1">2 (4)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Congestive heart failure</td>
                          <td rowspan="1" colspan="1">1 (2)</td>
                          <td rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Death</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Gastric ileus</td>
                          <td rowspan="1" colspan="1">1 (2)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Hemi-diaphragmatic paralysis</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Hemi-diaphragmatic paresis</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Infection</td>
                          <td rowspan="1" colspan="1">1 (2)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Pacemaker insertion</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Pain at wound site</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Pleural effusion</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Pseudo-aneurysm of femoral artery</td>
                          <td rowspan="1" colspan="1">1 (2)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="tblfn6">
                        <p>Data are presented as total number of patients with the event, <italic toggle="yes">n</italic> (%). There were 8 events in the CA arm (6 patients) and 10 in the SA arm (8 patients).</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <p>Improvements in patient-reported symptom and quality-of-life measures were seen from the first 3 months after ablation and sustained to the end of follow-up in both groups (<italic toggle="yes">Figure <xref rid="ehaa658-F3" ref-type="fig">3</xref></italic>). However, the differences in mean EHRA, AFEQT, and EQ-5D-5L scores at 12 months were significantly worse for SA than CA: 0.916 (<italic toggle="yes">P</italic> = 0.02), −6.74 (<italic toggle="yes">P</italic> = 0.05), and −0.079 (<italic toggle="yes">P</italic> = 0.02), respectively (Supplementary material <italic toggle="yes">Table A6</italic>). Over the 12-month follow-up, SA was associated with significantly lower QALYs than CA (0.78 vs. 0.85, <italic toggle="yes">P</italic> = 0.02) and higher costs which translated to an incremental net benefit of £4918 (95% CI: £1101–8735) for CA vs. SA at a conservative cost-effectiveness threshold of £20 000 per QALY (Supplementary material <italic toggle="yes">Table A6</italic>).</p>
                  <fig position="float" id="ehaa658-F3">
                    <label>Figure 3</label>
                    <caption>
                      <p>Changes in symptoms and health-related quality of life over time. AFEQT, AF Effect on QualiTy-of-life; CA, catheter ablation; EHRA, European Heart Rhythm Association score for AF; EQ-5D-5L VAS, quality of life questionnaire’s visual analogue scales; SA, surgical ablation.</p>
                    </caption>
                    <graphic xlink:href="ehaa658f3" position="float"/>
                  </fig>
                </sec>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>This is the first RCT to compare thoracoscopic SA with CA as the index procedure in LSPAF patients with rigorous follow-up using continuous cardiac monitoring and comprehensive analysis of symptoms, quality of life, and cost-effectiveness. The main finding was that SA conferred no benefit over CA in terms of freedom from AF/AT, AF burden reduction or in procedure-related serious adverse events. Catheter ablation was associated with greater symptom and quality-of-life improvement measured by disease-specific (AFEQT, EHRA) and generic health outcomes measures (EQ-5D-5L), was less costly, and hence more cost-effective than SA.</p>
              <p>The underlying substrate in paroxysmal AF responds well to PVI which can be achieved by CA with excellent results.<xref rid="ehaa658-B3" ref-type="bibr"><sup>3</sup></xref> In contrast, the LSPAF substrate is more advanced due to complex neurohormonal remodelling resulting in LA dilation and myocardial fibrosis which renders this arrhythmia difficult to treat with CA.<xref rid="ehaa658-B3" ref-type="bibr"><sup>3</sup></xref> Unsurprisingly, LSPAF is an area where there is a paucity of data and a genuine unmet need for optimal treatment.</p>
              <p>Our study is unique as the role of thoracoscopic SA as an index intervention in LSPAF has not been previously investigated in an RCT. Current guidelines recommend SA as a potential therapeutic option for symptomatic AF when CA has failed (IIaB) or for symptomatic drug-refractory persistent or LSPAF (IIaC).<xref rid="ehaa658-B3" ref-type="bibr"><sup>3</sup></xref></p>
              <p>Early standalone thoracoscopic SA studies showed promising arrhythmia-free outcomes with subsequent RCTs supporting this finding albeit in mixed AF populations.<xref rid="ehaa658-B17" ref-type="bibr"><sup>17</sup></xref>
 <sup>,</sup>
 <xref rid="ehaa658-B20" ref-type="bibr"><sup>20–22</sup></xref> The FAST study, reported significantly greater AF-free survival at 12 months without AADs in the SA group compared with CA (65.6% vs. 36.5%; <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.002), although the adverse event rate was considerably higher (34% vs. 16%).<xref rid="ehaa658-B19" ref-type="bibr"><sup>19</sup></xref> However, two-thirds of patients in this study had prior unsuccessful CA and 67% had paroxysmal AF. Further limitations of this study include lesion set heterogeneity, inconsistent verification of conduction block and intermittent 7-day ambulatory ECG monitoring. Similarly, Pokushalov <italic toggle="yes">et al.</italic>
 <xref rid="ehaa658-B21" ref-type="bibr"><sup>21</sup></xref> undertook an RCT with 64 patients who had previously failed initial CA. This was a mixed AF population and at 12 months, SA was associated with better AF-free survival compared with CA (81% vs. 47%; <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.004) based on continuous cardiac monitoring. Adiyaman <italic toggle="yes">et al.</italic>
 <xref rid="ehaa658-B22" ref-type="bibr"><sup>22</sup></xref> reported a small non-inferiority RCT in predominantly paroxysmal AF (74%) patients with continuous cardiac monitoring over 2 years of follow-up. SA was less effective in this study as 29% of patients were free from arrhythmia compared with 56% in CA group (log-rank <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.059), and 20% of SA patients had a major complication with none in the CA group.</p>
              <p>Our earlier non-randomized pilot study focused on finding the optimal index intervention to treat LSPAF. The results suggested SA may be superior to CA at 1 year as 73% vs. 32% of patients were free from AF/AT, using intermittent 7-day ambulatory ECG monitoring.<xref rid="ehaa658-B10" ref-type="bibr"><sup>10</sup></xref> We subsequently designed the CASA-AF RCT to definitively answer which technique was more effective as a first-line invasive strategy in LSPAF. We chose continuous cardiac monitoring to provide a comprehensive assessment of heart rhythm.<xref rid="ehaa658-B14" ref-type="bibr"><sup>14</sup></xref> In addition, we examined the effects of the two treatments on symptoms, quality of life, and health economic outcomes.</p>
              <p>All patients had <italic toggle="yes">de novo</italic> LSPAF with a median time from persistent AF diagnosis to ablation of just under 2 years. The CA freedom from AF/AT outcome in this trial is in line with previous reports.<xref rid="ehaa658-B9" ref-type="bibr"><sup>9</sup></xref> However, the SA outcomes were poorer than in previous studies, which most probably relates to a combination of baseline study population characteristics and intensity of follow-up with ILR in our study.<xref rid="ehaa658-B22" ref-type="bibr"><sup>22</sup></xref> Other fundamental differences are that previous studies included a high proportion of patients with paroxysmal AF who are known to respond well to treatment, and secondly, SA was conducted following initial failed CA. In essence, these were reverse staged hybrid procedures which extended or completed previous lesion sets, and the reported efficacy of SA in these studies was in fact the combined efficacy of two ablation procedures. Furthermore, we know that the use of continuous cardiac monitoring with ILR is more representative of the true rate of AF recurrence than intermittent monitoring methods, especially in asymptomatic patients.<xref rid="ehaa658-B23" ref-type="bibr"><sup>23</sup></xref> In fact, intermittent monitoring may overestimate the success rate of ablation procedures compared with continuous monitoring.<xref rid="ehaa658-B12" ref-type="bibr"><sup>12</sup></xref>
 <sup>,</sup>
 <xref rid="ehaa658-B13" ref-type="bibr"><sup>13</sup></xref> Finally, the evolution of CA techniques, including contact force catheters, high-density multielectrode mapping, and lesion prediction algorithms, has provided incremental benefits in durability of lesion sets thereby reducing the potential benefit of application of RF under direct vision to the myocardial tissues as performed in SA.<xref rid="ehaa658-B24" ref-type="bibr"><sup>24–26</sup></xref></p>
              <sec>
                <title>Clinical outcomes</title>
                <p>The primary endpoint we chose was based on the definition of AF ablation success from the 2012/2017 consensus document on AF ablation.<xref rid="ehaa658-B27" ref-type="bibr"><sup>27</sup></xref> From the clinical perspective, it is extremely stringent as patients may derive significant symptomatic relief from AF burden reduction, be deemed a clinical success, but fail the study endpoint. The clinical improvement, measured in this study by ≥75% reduction of AF/AT burden, with just one procedure and without AADs, was very encouraging for both procedures at around 70%. Given that these patients were highly symptomatic and in continuous AF for 2 years, this reduction in AF burden provided significant clinical benefit as demonstrated by the improvement from baseline in quality-of-life measures. The AF burden reduction may be a better indicator of positive clinical outcomes and therefore the use of continuous cardiac monitoring to accurately assess the burden of arrhythmia pre- and post-ablation is desirable.</p>
              </sec>
              <sec>
                <title>Safety outcomes</title>
                <p>In comparison to other trials, our procedure-related complication rates were low.<xref rid="ehaa658-B20" ref-type="bibr"><sup>20–22</sup></xref> However, one death occurred following SA and although there were no differences in serious adverse events within 30 days or 1 year between the groups, the overall adverse events rates during the 12-month follow-up were higher in the SA arm (<xref rid="sup1" ref-type="supplementary-material">Supplementary material <italic toggle="yes">Table A5</italic></xref>).</p>
              </sec>
              <sec>
                <title>Quality of life and health economics outcomes</title>
                <p>This study is the first to report change in symptoms, change in quality of life, and health economic outcomes for SA and CA. Our quality-of-life assessment was rigorous using three validated tools including AF specific and generic measures. We found consistent improvements in all measures from baseline to 12 months in both groups but the mean difference in scores at 12 months for all three measures were in favour of CA. This benefit in quality of life for CA may reflect the relatively more invasive nature of SA and the higher rate of late complications. Furthermore, over the 12 months of follow-up, CA was associated with a modest but statistically significant gain of 0.069 QALYs and NHS cost saving of £3534 per patient compared with SA. This translates to an incremental net benefit of £4918 for CA vs. SA at a conservative cost-effectiveness threshold of £20 000 per QALY. The estimated probability that CA was less costly and hence more cost-effective than SA was 98.9%.</p>
              </sec>
              <sec>
                <title>Limitations</title>
                <p>The main limitation of this study is that the interventions were performed in four highly specialized centres in the UK, which may have an impact on the generalizability of results. Secondly, the study was not double-blinded, as it was not possible given the very different access sites, invasiveness and operators required for the two procedures. Finally, thoracoscopic AF ablation which includes LAA exclusion may confer benefits in terms of reduced stroke and bleeding risks, which was not specifically addressed here.</p>
              </sec>
            </sec>
            <sec sec-type="conclusion">
              <title>Conclusion</title>
              <p>In this multi-centre RCT, we found that thoracoscopic SA is not superior to CA in establishing and maintaining normal SR in patients with LSPAF. Catheter ablation was associated with greater improvements in symptoms and quality of life and was more cost-effective than SA. We therefore recommend CA as the first-line interventional therapy for patients’ symptomatic LSPAF refractory to drug therapy.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary material</title>
              <p><xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> is available at <italic toggle="yes">European Heart Journal</italic> online.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="sup1" position="float" content-type="local-data">
                <label>ehaa658_Supplementary_Data</label>
                <media xlink:href="ehaa658_supplementary_data.zip">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="ack1">
              <title>Acknowledgements</title>
              <p>CASA-AF Investigators: <bold><italic toggle="yes">Consultant Cardiologists/Surgeons:</italic></bold> Rashmi Yahdev, Shelley Rahman-Halley, Joyce Wong, Aaisha Opel, Riyaz Kaba, Eva Nyktari, Esther Cambronero-Cortinas, Cemil Izgi, and Timothy Fairbairn. <italic toggle="yes"><bold>Data Acquisition/Analysis:</bold></italic> Royal Brompton and Harefield NHS Trust: Joanne Benton, Ruth Chester, Eliane Cunliffe, Lucy Edmondson, Matthew Gill, Vicky Griffiths, Rebecca Harman, Catherine Huggett, Jenny Keegan, Kevin Kirby, Karen Lascelles, Ramasamy Manivarmane, Iulia Munteanu, Karen O'Brien, Tess Phyl, Shelley Rahman-Halley, Tsveta Rahneva, Cheryl Riley, Paula Rogers, Katherine Smith, Rick Wage, Cathy West, Yakup Yakupoglu, and Guang Yang. <italic toggle="yes">Liverpool Heart and Chest Hospital:</italic> Audra Audraite, Sandra Belchambers, Susan Hughes, Maureen Morgan, Christina Ronayne, Rob Shaw, Paulinus Simkus, and Clive Taylerson. <italic toggle="yes">Brighton and Sussex University Hospitals NHS Trust</italic>: Chloe Bruce, Andrew McGregor, Catherine Thomson. DMC Members: Malcolm Walker (Chair), Gareth Ambler, and Ranjit Deshpande. <bold><italic toggle="yes">TSC Members:</italic></bold> William D. Toff (Chair), Tim Betts, Sylvia Clarke, Guy Haywood, Steven Hunter, and Trudie Lobban. <bold><italic toggle="yes">Adverse events independent review committee:</italic></bold> Malcolm Dalrymple-Hay, Chris Pepper, and Paul Ridley. <bold>ILR data quality control at Barts NHS Trust</bold>: Hollie Granville, Alice Snell, and Sophia John.</p>
              <sec>
                <title>Funding</title>
                <p>This work was supported by the Efficacy and Mechanism Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership (grant number 12/127/127). The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NIHR, or the Department of Health and Social Care.</p>
                <p><bold>Conflict of interest:</bold> none declared.</p>
              </sec>
            </ack>
            <ref-list id="ref1">
              <title>References</title>
              <ref id="ehaa658-B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chugh</surname>
 <given-names>SS</given-names></string-name>, <string-name><surname>Havmoeller</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Narayanan</surname>
 <given-names>K</given-names></string-name>, <string-name><surname>Singh</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Rienstra</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Benjamin</surname>
 <given-names>EJ</given-names></string-name>, <string-name><surname>Gillum</surname>
 <given-names>RF</given-names></string-name>, <string-name><surname>Kim</surname>
 <given-names>Y-H</given-names></string-name>, <string-name><surname>McAnulty</surname>
 <given-names>JH</given-names></string-name>, <string-name><surname>Zheng</surname>
 <given-names>Z-J</given-names></string-name>, <string-name><surname>Forouzanfar</surname>
 <given-names>MH</given-names></string-name>, <string-name><surname>Naghavi</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Mensah</surname>
 <given-names>GA</given-names></string-name>, <string-name><surname>Ezzati</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Murray</surname>
 <given-names>CJL.</given-names></string-name></person-group> 
 <article-title>Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study</article-title>. <source>Circulation</source>  <year>2014</year>;<volume>129</volume>:<fpage>837</fpage>–<lpage>847</lpage>.<pub-id pub-id-type="pmid">24345399</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benjamin</surname>
 <given-names>EJ</given-names></string-name>, <string-name><surname>Wolf</surname>
 <given-names>PA</given-names></string-name>, <string-name><surname>D’Agostino</surname>
 <given-names>RB</given-names></string-name>, <string-name><surname>Silbershatz</surname>
 <given-names>H</given-names></string-name>, <string-name><surname>Kannel</surname>
 <given-names>WB</given-names></string-name>, <string-name><surname>Levy</surname>
 <given-names>D.</given-names></string-name></person-group> 
 <article-title>Impact of atrial fibrillation on the risk of death: the Framingham heart study</article-title>. <source>Circulation</source>  <year>1998</year>;<volume>98</volume>:<fpage>946</fpage>–<lpage>952</lpage>.<pub-id pub-id-type="pmid">9737513</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kirchhof</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>Benussi</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Kotecha</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Ahlsson</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Atar</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Casadei</surname>
 <given-names>B</given-names></string-name>, <string-name><surname>Castella</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Diener</surname>
 <given-names>H-C</given-names></string-name>, <string-name><surname>Heidbuchel</surname>
 <given-names>H</given-names></string-name>, <string-name><surname>Hendriks</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Hindricks</surname>
 <given-names>G</given-names></string-name>, <string-name><surname>Manolis</surname>
 <given-names>AS</given-names></string-name>, <string-name><surname>Oldgren</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Popescu</surname>
 <given-names>BA</given-names></string-name>, <string-name><surname>Schotten</surname>
 <given-names>U</given-names></string-name>, <string-name><surname>Van Putte</surname>
 <given-names>B</given-names></string-name>, <string-name><surname>Vardas</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>Agewall</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Camm</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Baron Esquivias</surname>
 <given-names>G</given-names></string-name>, <string-name><surname>Budts</surname>
 <given-names>W</given-names></string-name>, <string-name><surname>Carerj</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Casselman</surname>
 <given-names>F</given-names></string-name>, <string-name><surname>Coca</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>De Caterina</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Deftereos</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Dobrev</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Ferro</surname>
 <given-names>JM</given-names></string-name>, <string-name><surname>Filippatos</surname>
 <given-names>G</given-names></string-name>, <string-name><surname>Fitzsimons</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Gorenek</surname>
 <given-names>B</given-names></string-name>, <string-name><surname>Guenoun</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Hohnloser</surname>
 <given-names>SH</given-names></string-name>, <string-name><surname>Kolh</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>Lip</surname>
 <given-names>GYH</given-names></string-name>, <string-name><surname>Manolis</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>McMurray</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Ponikowski</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>Rosenhek</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Ruschitzka</surname>
 <given-names>F</given-names></string-name>, <string-name><surname>Savelieva</surname>
 <given-names>I</given-names></string-name>, <string-name><surname>Sharma</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Suwalski</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>Tamargo</surname>
 <given-names>JL</given-names></string-name>, <string-name><surname>Taylor</surname>
 <given-names>CJ</given-names></string-name>, <string-name><surname>Van Gelder</surname>
 <given-names>IC</given-names></string-name>, <string-name><surname>Voors</surname>
 <given-names>AA</given-names></string-name>, <string-name><surname>Windecker</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Zamorano</surname>
 <given-names>JL</given-names></string-name>, <string-name><surname>Zeppenfeld</surname>
 <given-names>K.</given-names></string-name></person-group> 
 <article-title>2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS</article-title>. <source>Eur Heart J</source>  <year>2016</year>;<volume>37</volume>:<fpage>2893</fpage>–<lpage>2962</lpage>.<pub-id pub-id-type="pmid">27567408</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stewart</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Murphy</surname>
 <given-names>N</given-names></string-name>, <string-name><surname>Walker</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>McGuire</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>McMurray</surname>
 <given-names>JJV.</given-names></string-name></person-group> 
 <article-title>Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK</article-title>. <source>Heart</source>  <year>2004</year>;<volume>90</volume>:<fpage>286</fpage>–<lpage>292</lpage>.<pub-id pub-id-type="pmid">14966048</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Packer</surname>
 <given-names>DL</given-names></string-name>, <string-name><surname>Kowal</surname>
 <given-names>RC</given-names></string-name>, <string-name><surname>Wheelan</surname>
 <given-names>KR</given-names></string-name>, <string-name><surname>Irwin</surname>
 <given-names>JM</given-names></string-name>, <string-name><surname>Champagne</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Guerra</surname>
 <given-names>PG</given-names></string-name>, <string-name><surname>Dubuc</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Reddy</surname>
 <given-names>V</given-names></string-name>, <string-name><surname>Nelson</surname>
 <given-names>L</given-names></string-name>, <string-name><surname>Holcomb</surname>
 <given-names>RG</given-names></string-name>, <string-name><surname>Lehmann</surname>
 <given-names>JW</given-names></string-name>, <string-name><surname>Ruskin</surname>
 <given-names>JN.</given-names></string-name></person-group> 
 <article-title>Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation</article-title>. <source>J Am Coll Cardiol</source>  <year>2013</year>;<volume>61</volume>:<fpage>1713</fpage>–<lpage>1723</lpage>.<pub-id pub-id-type="pmid">23500312</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilber</surname>
 <given-names>DJ</given-names></string-name>, <string-name><surname>Pappone</surname>
 <given-names>C</given-names></string-name>, <string-name><surname>Neuzil</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>De Paola</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Marchlinski</surname>
 <given-names>F</given-names></string-name>, <string-name><surname>Natale</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Macle</surname>
 <given-names>L</given-names></string-name>, <string-name><surname>Daoud</surname>
 <given-names>EG</given-names></string-name>, <string-name><surname>Calkins</surname>
 <given-names>H</given-names></string-name>, <string-name><surname>Hall</surname>
 <given-names>B</given-names></string-name>, <string-name><surname>Reddy</surname>
 <given-names>V</given-names></string-name>, <string-name><surname>Augello</surname>
 <given-names>G</given-names></string-name>, <string-name><surname>Reynolds</surname>
 <given-names>MR</given-names></string-name>, <string-name><surname>Vinekar</surname>
 <given-names>C</given-names></string-name>, <string-name><surname>Liu</surname>
 <given-names>CY</given-names></string-name>, <string-name><surname>Berry</surname>
 <given-names>SM</given-names></string-name>, <string-name><surname>Berry</surname>
 <given-names>DA</given-names></string-name></person-group>. ThermoCool AF Trial Investigators 
<article-title>Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial</article-title>. <source>JAMA</source>  <year>2010</year>;<volume>303</volume>:<fpage>333</fpage>.<pub-id pub-id-type="pmid">20103757</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Verma</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Jiang</surname>
 <given-names>C</given-names></string-name>, <string-name><surname>Betts</surname>
 <given-names>TR</given-names></string-name>, <string-name><surname>Chen</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Deisenhofer</surname>
 <given-names>I</given-names></string-name>, <string-name><surname>Mantovan</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Macle</surname>
 <given-names>L</given-names></string-name>, <string-name><surname>Morillo</surname>
 <given-names>CA</given-names></string-name>, <string-name><surname>Haverkamp</surname>
 <given-names>W</given-names></string-name>, <string-name><surname>Weerasooriya</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Albenque</surname>
 <given-names>J-P</given-names></string-name>, <string-name><surname>Nardi</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Menardi</surname>
 <given-names>E</given-names></string-name>, <string-name><surname>Novak</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>Sanders</surname>
 <given-names>P.</given-names></string-name></person-group> 
 <article-title>Approaches to catheter ablation for persistent atrial fibrillation</article-title>. <source>N Engl J Med</source>  <year>2015</year>;<volume>372</volume>:<fpage>1812</fpage>–<lpage>1822</lpage>.<pub-id pub-id-type="pmid">25946280</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rostock</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Salukhe</surname>
 <given-names>TV</given-names></string-name>, <string-name><surname>Steven</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Drewitz</surname>
 <given-names>I</given-names></string-name>, <string-name><surname>Hoffmann</surname>
 <given-names>BA</given-names></string-name>, <string-name><surname>Bock</surname>
 <given-names>K</given-names></string-name>, <string-name><surname>Servatius</surname>
 <given-names>H</given-names></string-name>, <string-name><surname>Müllerleile</surname>
 <given-names>K</given-names></string-name>, <string-name><surname>Sultan</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Gosau</surname>
 <given-names>N</given-names></string-name>, <string-name><surname>Meinertz</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Wegscheider</surname>
 <given-names>K</given-names></string-name>, <string-name><surname>Willems</surname>
 <given-names>S.</given-names></string-name></person-group> 
 <article-title>Long-term single- and multiple-procedure outcome and predictors of success after catheter ablation for persistent atrial fibrillation</article-title>. <source>Heart Rhythm</source>  <year>2011</year>;<volume>8</volume>:<fpage>1391</fpage>–<lpage>1397</lpage>.<pub-id pub-id-type="pmid">21699825</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clarnette</surname>
 <given-names>JA</given-names></string-name>, <string-name><surname>Brooks</surname>
 <given-names>AG</given-names></string-name>, <string-name><surname>Mahajan</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Elliott</surname>
 <given-names>AD</given-names></string-name>, <string-name><surname>Twomey</surname>
 <given-names>DJ</given-names></string-name>, <string-name><surname>Pathak</surname>
 <given-names>RK</given-names></string-name>, <string-name><surname>Kumar</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Munawar</surname>
 <given-names>DA</given-names></string-name>, <string-name><surname>Young</surname>
 <given-names>GD</given-names></string-name>, <string-name><surname>Kalman</surname>
 <given-names>JM</given-names></string-name>, <string-name><surname>Lau</surname>
 <given-names>DH</given-names></string-name>, <string-name><surname>Sanders</surname>
 <given-names>P.</given-names></string-name></person-group> 
 <article-title>Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a systematic review and meta-analysis</article-title>. <source>Europace</source>  <year>2018</year>;<volume>20</volume>:<fpage>f366</fpage>–<lpage>f376</lpage>.<pub-id pub-id-type="pmid">29267853</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haldar</surname>
 <given-names>SK</given-names></string-name>, <string-name><surname>Jones</surname>
 <given-names>DG</given-names></string-name>, <string-name><surname>Bahrami</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>De Souza</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Panikker</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Butcher</surname>
 <given-names>C</given-names></string-name>, <string-name><surname>Khan</surname>
 <given-names>H</given-names></string-name>, <string-name><surname>Yahdav</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Jarman</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Mantziari</surname>
 <given-names>L</given-names></string-name>, <string-name><surname>Nyktari</surname>
 <given-names>E</given-names></string-name>, <string-name><surname>Mohiaddin</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Hussain</surname>
 <given-names>W</given-names></string-name>, <string-name><surname>Markides</surname>
 <given-names>V</given-names></string-name>, <string-name><surname>Wong</surname>
 <given-names>T.</given-names></string-name></person-group> 
 <article-title>Catheter ablation vs electrophysiologically guided thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: the CASA-AF Study</article-title>. <source>Heart Rhythm</source>  <year>2017</year>;<volume>14</volume>:<fpage>1596</fpage>–<lpage>1603</lpage>.<pub-id pub-id-type="pmid">29101964</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Edgerton</surname>
 <given-names>JR</given-names></string-name>, <string-name><surname>Jackman</surname>
 <given-names>WM</given-names></string-name>, <string-name><surname>Mahoney</surname>
 <given-names>C</given-names></string-name>, <string-name><surname>Mack</surname>
 <given-names>MJ.</given-names></string-name></person-group> 
 <article-title>Totally thorascopic surgical ablation of persistent AF and long-standing persistent atrial fibrillation using the “Dallas” lesion set</article-title>. <source>Heart Rhythm</source>  <year>2009</year>;<volume>6</volume>:<fpage>S64</fpage>–<lpage>S70</lpage>.<pub-id pub-id-type="pmid">19959146</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanke</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Charitos</surname>
 <given-names>EI</given-names></string-name>, <string-name><surname>Stierle</surname>
 <given-names>U</given-names></string-name>, <string-name><surname>Karluss</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Kraatz</surname>
 <given-names>E</given-names></string-name>, <string-name><surname>Graf</surname>
 <given-names>B</given-names></string-name>, <string-name><surname>Hagemann</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Misfeld</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Sievers</surname>
 <given-names>HH.</given-names></string-name></person-group> 
 <article-title>Twenty-four-hour Holter Monitor follow-up does not provide accurate heart rhythm status after surgical atrial fibrillation ablation therapy: up to 12 months experience with a novel permanently implantable heart rhythm monitor device</article-title>. <source>Circulation</source>  <year>2009</year>;<volume>120</volume>:<fpage>S177</fpage>–<lpage>S184</lpage>.<pub-id pub-id-type="pmid">19752365</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wechselberger</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Kronborg</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Huo</surname>
 <given-names>Y</given-names></string-name>, <string-name><surname>Piorkowski</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Neudeck</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Päßler</surname>
 <given-names>E</given-names></string-name>, <string-name><surname>El-Armouche</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Richter</surname>
 <given-names>U</given-names></string-name>, <string-name><surname>Mayer</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Ulbrich</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Pu</surname>
 <given-names>L</given-names></string-name>, <string-name><surname>Kirstein</surname>
 <given-names>B</given-names></string-name>, <string-name><surname>Gaspar</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Piorkowski</surname>
 <given-names>C.</given-names></string-name></person-group> 
 <article-title>Continuous monitoring after atrial fibrillation ablation: the LINQ AF study</article-title>. <source>Europace</source>  <year>2018</year>;<volume>20</volume>:<fpage>f312</fpage>–<lpage>f320</lpage>.<pub-id pub-id-type="pmid">29688326</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Balabanski</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Brugada</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Arbelo</surname>
 <given-names>E</given-names></string-name>, <string-name><surname>Laroche</surname>
 <given-names>C</given-names></string-name>, <string-name><surname>Maggioni</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Blomström-Lundqvist</surname>
 <given-names>C</given-names></string-name>, <string-name><surname>Kautzner</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Tavazzi</surname>
 <given-names>L</given-names></string-name>, <string-name><surname>Tritto</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Kulakowski</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>Kalejs</surname>
 <given-names>O</given-names></string-name>, <string-name><surname>Forster</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Villalobos</surname>
 <given-names>FS</given-names></string-name>, <string-name><surname>Dagres</surname>
 <given-names>N</given-names></string-name></person-group>, on behalf of the ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators Group. 
<article-title>Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry</article-title>. <source>Europace</source>  <year>2019</year>;<volume>21</volume>:<fpage>1802</fpage>–<lpage>1808</lpage>.<pub-id pub-id-type="pmid">31693093</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Agha</surname>
 <given-names>RA</given-names></string-name>, <string-name><surname>Altman</surname>
 <given-names>DG</given-names></string-name>, <string-name><surname>Rosin</surname>
 <given-names>D.</given-names></string-name></person-group> 
 <article-title>The SPIRIT 2013 statement—defining standard protocol items for trials</article-title>. <source>Int J Surg</source>  <year>2015</year>;<volume>13</volume>:<fpage>288</fpage>–<lpage>291</lpage>.<pub-id pub-id-type="pmid">25498499</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khan</surname>
 <given-names>HR</given-names></string-name>, <string-name><surname>Kralj-Hans</surname>
 <given-names>I</given-names></string-name>, <string-name><surname>Haldar</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Bahrami</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Clague</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>De Souza</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Francis</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Hussain</surname>
 <given-names>W</given-names></string-name>, <string-name><surname>Jarman</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Jones</surname>
 <given-names>DG</given-names></string-name>, <string-name><surname>Mediratta</surname>
 <given-names>N</given-names></string-name>, <string-name><surname>Mohiaddin</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Salukhe</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Jones</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Lord</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Murphy</surname>
 <given-names>C</given-names></string-name>, <string-name><surname>Kelly</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Markides</surname>
 <given-names>V</given-names></string-name>, <string-name><surname>Gupta</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Wong</surname>
 <given-names>T.</given-names></string-name></person-group> 
 <article-title>Catheter ablation versus thoracoscopic surgical ablation in long standing persistent atrial fibrillation (CASA-AF): study protocol for a randomised controlled trial</article-title>. <source>Trials</source>  <year>2018</year>;<volume>19</volume>:<fpage>117</fpage>.<pub-id pub-id-type="pmid">29458408</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krul</surname>
 <given-names>SPJ</given-names></string-name>, <string-name><surname>Driessen</surname>
 <given-names>AHG</given-names></string-name>, <string-name><surname>Boven</surname>
 <given-names>WV</given-names></string-name>, <string-name><surname>Linnenbank</surname>
 <given-names>AC</given-names></string-name>, <string-name><surname>Geuzebroek</surname>
 <given-names>GSC</given-names></string-name>, <string-name><surname>Jackman</surname>
 <given-names>WM</given-names></string-name>, <string-name><surname>Wilde</surname>
 <given-names>AAM</given-names></string-name>, <string-name><surname>Bakker</surname>
 <given-names>JD</given-names></string-name>, <string-name><surname>Groot</surname>
 <given-names>JD.</given-names></string-name></person-group> 
 <article-title>Thoracoscopic video-assisted pulmonary vein antrum isolation, ganglionated plexus ablation, and periprocedural confirmation of ablation lesions: first results of a hybrid surgical-electrophysiological approach for atrial fibrillation</article-title>. <source>Circ Arrhythm Electrophysiol</source>  <year>2011</year>;<volume>4</volume>:<fpage>262</fpage>–<lpage>270</lpage>.<pub-id pub-id-type="pmid">21493960</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sanders</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>Pürerfellner</surname>
 <given-names>H</given-names></string-name>, <string-name><surname>Pokushalov</surname>
 <given-names>E</given-names></string-name>, <string-name><surname>Sarkar</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Di Bacco</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Maus</surname>
 <given-names>B</given-names></string-name>, <string-name><surname>Dekker</surname>
 <given-names>LRC.</given-names></string-name></person-group> 
 <article-title>Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: results from the Reveal LINQ Usability Study</article-title>. <source>Heart Rhythm</source>  <year>2016</year>;<volume>13</volume>:<fpage>1425</fpage>–<lpage>1430</lpage>.<pub-id pub-id-type="pmid">26961298</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hout</surname>
 <given-names>BV</given-names></string-name>, <string-name><surname>Janssen</surname>
 <given-names>MF</given-names></string-name>, <string-name><surname>Feng</surname>
 <given-names>Y-S</given-names></string-name>, <string-name><surname>Kohlmann</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Busschbach</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Golicki</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Lloyd</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Scalone</surname>
 <given-names>L</given-names></string-name>, <string-name><surname>Kind</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>Pickard</surname>
 <given-names>AS.</given-names></string-name></person-group> 
 <article-title>Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets</article-title>. <source>Value Health</source>  <year>2012</year>;<volume>15</volume>:<fpage>708</fpage>–<lpage>715</lpage>.<pub-id pub-id-type="pmid">22867780</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boersma</surname>
 <given-names>LVA</given-names></string-name>, <string-name><surname>Castella</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Boven</surname>
 <given-names>WV</given-names></string-name>, <string-name><surname>Berruezo</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Yilmaz</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Nadal</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Sandoval</surname>
 <given-names>E</given-names></string-name>, <string-name><surname>Calvo</surname>
 <given-names>N</given-names></string-name>, <string-name><surname>Brugada</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Kelder</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Wijffels</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Mont</surname>
 <given-names>L.</given-names></string-name></person-group> 
 <article-title>Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial</article-title>. <source>Circulation</source>  <year>2012</year>;<volume>125</volume>:<fpage>23</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">22082673</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pokushalov</surname>
 <given-names>E</given-names></string-name>, <string-name><surname>Romanov</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Elesin</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Bogachev-Prokophiev</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Losik</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Bairamova</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Karaskov</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Steinberg</surname>
 <given-names>JS.</given-names></string-name></person-group> 
 <article-title>Catheter versus surgical ablation of atrial fibrillation after a failed initial pulmonary vein isolation procedure: a randomized controlled trial: catheter versus surgical ablation</article-title>. <source>J Cardiovasc Electrophysiol</source>  <year>2013</year>;<volume>24</volume>:<fpage>1338</fpage>–<lpage>1343</lpage>.<pub-id pub-id-type="pmid">24016147</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adiyaman</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Buist</surname>
 <given-names>TJ</given-names></string-name>, <string-name><surname>Beukema</surname>
 <given-names>RJ</given-names></string-name>, <string-name><surname>Smit</surname>
 <given-names>JJJ</given-names></string-name>, <string-name><surname>Delnoy</surname>
 <given-names>PPHM</given-names></string-name>, <string-name><surname>Hemels</surname>
 <given-names>MEW</given-names></string-name>, <string-name><surname>Sie</surname>
 <given-names>HT</given-names></string-name>, <string-name><surname>Ramdat Misier</surname>
 <given-names>AR</given-names></string-name>, <string-name><surname>Elvan</surname>
 <given-names>A.</given-names></string-name></person-group> 
 <article-title>Randomized controlled trial of surgical versus catheter ablation for paroxysmal and early persistent atrial fibrillation</article-title>. <source>Circ Arrhythm Electrophysiol</source>  <year>2018</year>;<volume>11</volume>:e006182.</mixed-citation>
              </ref>
              <ref id="ehaa658-B23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sanna</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Diener</surname>
 <given-names>H-C</given-names></string-name>, <string-name><surname>Passman</surname>
 <given-names>RS</given-names></string-name>, <string-name><surname>Di Lazzaro</surname>
 <given-names>V</given-names></string-name>, <string-name><surname>Bernstein</surname>
 <given-names>RA</given-names></string-name>, <string-name><surname>Morillo</surname>
 <given-names>CA</given-names></string-name>, <string-name><surname>Rymer</surname>
 <given-names>MM</given-names></string-name>, <string-name><surname>Thijs</surname>
 <given-names>V</given-names></string-name>, <string-name><surname>Rogers</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Beckers</surname>
 <given-names>F</given-names></string-name>, <string-name><surname>Lindborg</surname>
 <given-names>K</given-names></string-name>, <string-name><surname>Brachmann</surname>
 <given-names>J.</given-names></string-name></person-group> 
 <article-title>Cryptogenic stroke and underlying atrial fibrillation</article-title>. <source>N Engl J Med</source>  <year>2014</year>;<volume>370</volume>:<fpage>2478</fpage>–<lpage>2486</lpage>.<pub-id pub-id-type="pmid">24963567</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haldar</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Jarman</surname>
 <given-names>JWE</given-names></string-name>, <string-name><surname>Panikker</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Jones</surname>
 <given-names>DG</given-names></string-name>, <string-name><surname>Salukhe</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Gupta</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Wynn</surname>
 <given-names>G</given-names></string-name>, <string-name><surname>Hussain</surname>
 <given-names>W</given-names></string-name>, <string-name><surname>Markides</surname>
 <given-names>V</given-names></string-name>, <string-name><surname>Wong</surname>
 <given-names>T.</given-names></string-name></person-group> 
 <article-title>Contact force sensing technology identifies sites of inadequate contact and reduces acute pulmonary vein reconnection: a prospective case control study</article-title>. <source>Int J Cardiol</source>  <year>2013</year>;<volume>168</volume>:<fpage>1160</fpage>–<lpage>1166</lpage>.<pub-id pub-id-type="pmid">23219078</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Segerson</surname>
 <given-names>NM</given-names></string-name>, <string-name><surname>Lynch</surname>
 <given-names>B</given-names></string-name>, <string-name><surname>Mozes</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Marks</surname>
 <given-names>MM</given-names></string-name>, <string-name><surname>Noonan</surname>
 <given-names>DK</given-names></string-name>, <string-name><surname>Gordon</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Jais</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>Daccarett</surname>
 <given-names>M.</given-names></string-name></person-group> 
 <article-title>High-density mapping and ablation of concealed low-voltage activity within pulmonary vein antra results in improved freedom from atrial fibrillation compared to pulmonary vein isolation alone</article-title>. <source>Heart Rhythm</source>  <year>2018</year>;<volume>15</volume>:<fpage>1158</fpage>–<lpage>1164</lpage>.<pub-id pub-id-type="pmid">29729399</pub-id></mixed-citation>
              </ref>
              <ref id="ehaa658-B26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hussein</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Das</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Riva</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Morgan</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Ronayne</surname>
 <given-names>C</given-names></string-name>, <string-name><surname>Sahni</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Shaw</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Todd</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Hall</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Modi</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Natale</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Dello Russo</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Snowdon</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Gupta</surname>
 <given-names>D.</given-names></string-name></person-group> 
 <article-title>Use of ablation index-guided ablation results in high rates of durable pulmonary vein isolation and freedom from arrhythmia in persistent atrial fibrillation patients: the PRAISE study results</article-title>. <source>Circ Arrhythm Electrophysiol</source>  <year>2018</year>;<volume>11</volume>:<fpage>888</fpage>–<lpage>895</lpage>.</mixed-citation>
              </ref>
              <ref id="ehaa658-B27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Calkins</surname>
 <given-names>H</given-names></string-name>, <string-name><surname>Hindricks</surname>
 <given-names>G</given-names></string-name>, <string-name><surname>Cappato</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Kim</surname>
 <given-names>Y-H</given-names></string-name>, <string-name><surname>Saad</surname>
 <given-names>EB</given-names></string-name>, <string-name><surname>Aguinaga</surname>
 <given-names>L</given-names></string-name>, <string-name><surname>Akar</surname>
 <given-names>JG</given-names></string-name>, <string-name><surname>Badhwar</surname>
 <given-names>V</given-names></string-name>, <string-name><surname>Brugada</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Camm</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Chen</surname>
 <given-names>P-S</given-names></string-name>, <string-name><surname>Chen</surname>
 <given-names>S-A</given-names></string-name>, <string-name><surname>Chung</surname>
 <given-names>MK</given-names></string-name>, <string-name><surname>Nielsen</surname>
 <given-names>JC</given-names></string-name>, <string-name><surname>Curtis</surname>
 <given-names>AB</given-names></string-name>, <string-name><surname>Davies</surname>
 <given-names>DW</given-names></string-name>, <string-name><surname>Day</surname>
 <given-names>JD</given-names></string-name>, <string-name><surname>d’Avila</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>de Groot</surname>
 <given-names>NMS(N)</given-names></string-name>, <string-name><surname>Di Biase</surname>
 <given-names>L</given-names></string-name>, <string-name><surname>Duytschaever</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Edgerton</surname>
 <given-names>JR</given-names></string-name>, <string-name><surname>Ellenbogen</surname>
 <given-names>KA</given-names></string-name>, <string-name><surname>Ellinor</surname>
 <given-names>PT</given-names></string-name>, <string-name><surname>Ernst</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Fenelon</surname>
 <given-names>G</given-names></string-name>, <string-name><surname>Gerstenfeld</surname>
 <given-names>EP</given-names></string-name>, <string-name><surname>Haines</surname>
 <given-names>DE</given-names></string-name>, <string-name><surname>Haissaguerre</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Helm</surname>
 <given-names>RH</given-names></string-name>, <string-name><surname>Hylek</surname>
 <given-names>E</given-names></string-name>, <string-name><surname>Jackman</surname>
 <given-names>WM</given-names></string-name>, <string-name><surname>Jalife</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Kalman</surname>
 <given-names>JM</given-names></string-name>, <string-name><surname>Kautzner</surname>
 <given-names>J</given-names></string-name>, <string-name><surname>Kottkamp</surname>
 <given-names>H</given-names></string-name>, <string-name><surname>Kuck</surname>
 <given-names>KH</given-names></string-name>, <string-name><surname>Kumagai</surname>
 <given-names>K</given-names></string-name>, <string-name><surname>Lee</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Lewalter</surname>
 <given-names>T</given-names></string-name>, <string-name><surname>Lindsay</surname>
 <given-names>BD</given-names></string-name>, <string-name><surname>Macle</surname>
 <given-names>L</given-names></string-name>, <string-name><surname>Mansour</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Marchlinski</surname>
 <given-names>FE</given-names></string-name>, <string-name><surname>Michaud</surname>
 <given-names>GF</given-names></string-name>, <string-name><surname>Nakagawa</surname>
 <given-names>H</given-names></string-name>, <string-name><surname>Natale</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Nattel</surname>
 <given-names>S</given-names></string-name>, <string-name><surname>Okumura</surname>
 <given-names>K</given-names></string-name>, <string-name><surname>Packer</surname>
 <given-names>D</given-names></string-name>, <string-name><surname>Pokushalov</surname>
 <given-names>E</given-names></string-name>, <string-name><surname>Reynolds</surname>
 <given-names>MR</given-names></string-name>, <string-name><surname>Sanders</surname>
 <given-names>P</given-names></string-name>, <string-name><surname>Scanavacca</surname>
 <given-names>M</given-names></string-name>, <string-name><surname>Schilling</surname>
 <given-names>R</given-names></string-name>, <string-name><surname>Tondo</surname>
 <given-names>C</given-names></string-name>, <string-name><surname>Tsao</surname>
 <given-names>H-M</given-names></string-name>, <string-name><surname>Verma</surname>
 <given-names>A</given-names></string-name>, <string-name><surname>Wilber</surname>
 <given-names>DJ</given-names></string-name>, <string-name><surname>Yamane</surname>
 <given-names>T.</given-names></string-name></person-group> 
 <article-title>2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation</article-title>. <source>Heart Rhythm</source>  <year>2017</year>;<volume>14</volume>:<fpage>e275</fpage>–<lpage>e444</lpage>.<pub-id pub-id-type="pmid">28506916</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
